Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gadobenate dimeglumine

Drug Profile

Gadobenate dimeglumine

Alternative Names: B-19036; B-19036/7; E 7155; Gadobenic acid; Gd-BOPTA/Dimeg; MultiHance

Latest Information Update: 06 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bracco Diagnostics
  • Class Diagnostic agents; Gadolinium-containing contrast agents; Hexosamines; Organometallic compounds; Small molecules; Sugar alcohols
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Arterial occlusive disorders; CNS disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Jan 2018 The label for gadobenate dimeglumine contains a black box warning for nephrogenic systemic fibrosis
  • 30 Jan 2018 The US Food and Drug Administration approves gadobenate dimeglumine for CNS disorders (Diagnosis, In neonates, In infants) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top